证券研究报告 2026 年 01 月 17 日 湘财证券研究所 行业研究 医疗服务行业周报 政策力促银发经济升级，两大方向直接受益 --医疗服务行业周报 1.12-1.16 相关研究： 核心要点： 本周医药生物下跌 0.68%，涨跌幅排名位列申万一级行业第 19 位 根据 Wind 数据，本周申万一级行业医药生物下跌 0.68%，涨幅排名位列申 万 31 个一级行业第 19 位。沪深 300 指数下跌 0.57%，医药跑输沪深 300 指数 0.11 个百分点。申万医药生物二级子行业医疗服务 II 报收 7048.32 点，上涨 3.29%；中药 II 报收 6414.65 点，下跌 1.00%；化学制药Ⅱ报收 13656.41 点，下跌 2.40%；生物制品Ⅱ报收 6506.32 点，下跌 1.21%；医 药商业Ⅱ报收 5587.64 点，下跌 2.33%；医疗器械 II 报收 6896.75 点，下 跌 0.22%。 根据 Wind 数据，从医疗服务板块公司的表现来看，表现居前的公司有： 美年健康（+25.0%）、迪安诊断（+16.3%）、泓博医药（+13.0%）、兰卫医 学（+12.2%）、诺思格（+1 ...

Investment Rating - The industry investment rating for the medical biology sector is "Hold" [2]. Core Insights - The report highlights significant advancements in the brain-computer interface (BCI) industry, emphasizing the acceleration of industrial development and the establishment of a robust innovation ecosystem [3][4]. - The Shanghai Municipal Government has released a plan to cultivate the BCI industry, aiming for clinical applications of semi-invasive and invasive BCI products by 2027, with a comprehensive application by 2030 [4]. - The report suggests that the BCI field is entering a rapid development phase, driven by the release of industry standards and supportive government policies [7]. Summary by Sections Industry Overview - The BCI industry is experiencing accelerated industrialization, with recent breakthroughs in invasive devices and the establishment of new treatment paradigms for conditions like epilepsy [4][6]. - The report notes the importance of integrating BCI technology with artificial intelligence and virtual reality to enhance product offerings and market reach [4]. Government Initiatives - The Shanghai action plan outlines key milestones, including the development of over five invasive and semi-invasive BCI products for clinical trials and the establishment of a national-level BCI industry development zone [4]. - The plan also emphasizes the need for collaboration between innovative entities and medical institutions to foster product development in various applications, including rehabilitation and education [4]. Investment Recommendations - The report recommends focusing on companies such as Innovation Medical, Aipeng Medical, and Sanbo Brain Science, which are positioned to benefit from the growing BCI market [7].

Core Viewpoint - The brain-computer interface (BCI) sector in the A-share market has shown significant activity at the beginning of 2026, with a cumulative increase of 18.04% in the BCI theme index as of January 16, 2026, indicating a strong interest and potential for commercialization in this emerging industry [2][4]. Industry Overview - The BCI industry is projected to reach a market size of trillions, transitioning from laboratory research to commercial applications, driven by advancements in technology and supportive government policies [3]. - The Ministry of Industry and Information Technology and other departments have emphasized the importance of BCI in their strategic plans, including its inclusion in the "14th Five-Year Plan" for future industrial development [3]. Market Performance - As of January 16, 2026, the total market capitalization of 26 listed companies in the BCI sector has increased by approximately 108.7 billion yuan over ten trading days [8]. - Notable companies like Innovation Medical and Meihua Medical have experienced significant stock price fluctuations, reflecting the volatile nature of the market and investor sentiment towards BCI technologies [5][7]. Company Developments - Innovation Medical's subsidiary, Boling Brain Machine Technology, has launched products aimed at rehabilitation for stroke patients, although it reported operating losses of 6.6 million yuan and 8.66 million yuan in 2023 and 2024, respectively [6]. - Meihua Medical, a leader in cochlear implants, is actively collaborating with BCI clients to facilitate the transition from laboratory research to commercial production, highlighting the interconnectedness of BCI and existing medical technologies [7]. Strategic Collaborations - Companies like Yahui Long and Shenzhen Brain Machine Star Chain Technology have entered strategic partnerships to develop BCI-related products, aiming to enhance diagnostic and treatment capabilities in central nervous system diseases [9]. - Aipeng Medical is also expanding its business into BCI applications, focusing on pain management and sleep disorders, indicating a broader trend of diversification within the medical device sector [9]. Technical Insights - The core technological barriers in the BCI industry are concentrated in the upstream supply chain, including hardware components and surgical techniques, with significant potential for growth in domestic market penetration and localization [10].

Core Viewpoint - The Shandong provincial government is implementing comprehensive reforms in drug and medical device regulation to promote high-quality development in the pharmaceutical industry [1] Group 1: Policy and Strategic Initiatives - The Shandong Provincial Science and Technology Department is focusing on key technology breakthroughs and innovation platform construction to enhance the pharmaceutical industry's competitiveness [3] - The province plans to support nearly 1,000 major scientific innovation projects in the pharmaceutical sector by 2025, with over 300 million yuan in financial support [3] - The province has established 124 innovation platforms, including national and provincial key laboratories, to foster collaboration between leading enterprises and quality medical institutions [3] Group 2: Financial Support and Incentives - The government is increasing policy support for major innovative products, offering up to 40% of R&D investment as funding support for clinical trials, with maximum amounts of 10 million, 20 million, and 30 million yuan for different phases [4] - Over the past two years, 31 companies have received a total of 241 million yuan in R&D subsidies, effectively supporting the development of innovative drugs with strong efficacy and good industrialization prospects [4] Group 3: Future Directions - The provincial government aims to enhance the aggregation and allocation of innovation resources, including projects, platforms, and funding, to strengthen the technological support for high-quality development in the pharmaceutical industry [4][5] - Continuous efforts will be made to address the challenges in the pharmaceutical industry through various innovative approaches, including competitive bidding and targeted commissioning for key R&D tasks [4]

Core Viewpoint - The Shandong Provincial Government has issued a policy document aimed at deepening the reform of drug and medical device regulation to promote high-quality development in the pharmaceutical industry, marking a significant step in balancing drug safety and industrial growth [6][11]. Group 1: Policy Implementation - The document outlines 29 measures across six key areas to enhance the innovation and development of the pharmaceutical industry [7]. - It emphasizes the importance of drug and medical devices as critical goods related to public health and safety, as well as economic development [4]. Group 2: Key Measures - Strengthening the cultivation of pharmaceutical innovation by supporting cutting-edge technology, enhancing innovation platforms, and promoting the transformation of innovative drugs and devices [7]. - Optimizing the clinical trial ecosystem by encouraging medical institutions to undertake trials, improving ethical review efficiency, and applying AI technology [8]. - Deepening review and approval reforms, including proactive engagement with national drug regulatory bodies and supporting segmented production of drugs [9][10]. Group 3: Industry Growth and Internationalization - Promoting the international development of the industry through targeted investment attraction and enhancing international cooperation [9]. - Encouraging the clinical promotion and use of innovative products by establishing product directories and improving insurance payment mechanisms [8]. Group 4: Quality Supervision - Strengthening quality supervision throughout the entire process, ensuring corporate responsibility, and enhancing smart regulatory capabilities [10][13]. - Implementing a comprehensive regulatory framework to ensure drug safety and efficacy, utilizing big data and AI for monitoring [13]. Group 5: Collaborative Efforts - Enhancing collaboration among various departments such as technology, health, and drug regulation to create a seamless connection between clinical trials, usage, and insurance coverage [12]. - Establishing a mechanism for mutual recognition of ethical reviews in multi-center clinical trials to reduce costs and time for enterprises [12]. Group 6: Future Directions - The Shandong Provincial Drug Administration will work with relevant departments to ensure drug safety and support the high-quality development of the pharmaceutical industry [13].

Group 1 - The core viewpoint of the news is that Innovation Medical has experienced significant stock price fluctuations, with a year-to-date increase of 44.86% but a recent decline of 10.05% over the last five trading days [1] - As of January 16, the stock price was reported at 31.16 yuan per share, with a total market capitalization of 13.75 billion yuan [1] - The company has seen a net outflow of main funds amounting to 6.84 million yuan, with significant trading activity reflected in the large buy and sell orders [1] Group 2 - Innovation Medical operates primarily in the medical services sector, with 99.73% of its revenue coming from medical services [2] - The company reported a revenue of 597 million yuan for the period from January to September 2025, showing a year-on-year decrease of 2.11%, while net profit increased by 116.97% to 4.72 million yuan [2] - The number of shareholders has increased to 130,200, a rise of 58.75%, while the average circulating shares per person decreased by 37.01% [2]

Core Viewpoint - Shenzhen Beixin Life Technology Co., Ltd. has officially initiated its A-share listing process on the Shanghai Stock Exchange's Sci-Tech Innovation Board, aiming to raise approximately 9.52 billion yuan through the issuance of 57 million shares, which will account for 13.67% of the total share capital post-issuance [1] Group 1: Company Overview - Beixin Life focuses on the research, development, production, and sales of innovative medical devices for precise diagnosis and treatment of cardiovascular diseases [1] - The company has developed the first domestically produced 60MHz high-definition IVUS product and the first domestically approved FFR measurement system in China [1] Group 2: Product Development and Market Position - As of September 30, 2025, Beixin Life has launched 11 products and has 6 products under development, covering five major categories: IVUS systems, FFR systems, vascular access products, shockwave balloon therapy systems, and electrophysiological solutions [2] - The FFR system captured a 30.6% market share in China shortly after its launch in 2020, with over 70% of its domestic usage coming from tertiary hospitals [2] Group 3: Financial Performance and Projections - Beixin Life's revenue is projected to grow significantly, with expected revenues of 520 million to 560 million yuan in 2025, representing a year-on-year growth of 64.24% to 76.88% [3] - The company anticipates a substantial increase in net profit, with estimates ranging from 78 million to 88 million yuan, reflecting a year-on-year growth of 278.91% to 301.85% [3] Group 4: Strategic Initiatives and Future Outlook - The funds raised from the IPO will be primarily allocated to the construction of an industrialization base for interventional medical devices, R&D projects, and to supplement working capital [3] - The company aims to enhance its capital structure, reduce debt risk, and improve its resilience against market fluctuations, while also expanding production capacity and strengthening R&D capabilities [3]

Group 1 - The company, Beixin Life (688712.SH), plans to publicly issue 57 million shares, accounting for 13.67% of the total share capital after the issuance [1] - The initial strategic placement will involve 11.4 million shares, representing 20% of the total issuance, with senior management and core employees participating in a special asset management plan for 5.7 million shares, which is 10% of the total issuance [1] - The initial strategic placement by the sponsoring institution, China International Capital Corporation Wealth Securities Co., Ltd., is expected to be 2.85 million shares, or 5% of the total issuance, with a subscription amount not exceeding 40 million yuan [1] Group 2 - The company specializes in innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, recognized as a national high-tech enterprise [2] - The core products include the intravascular ultrasound (IVUS) diagnostic system, the first domestically developed 60MHz high-definition IVUS product approved by the National Medical Products Administration, and the flow reserve fraction (FFR) measurement system, the first domestic product in the FFR field approved by the same authority [2] - The company reported net profits attributable to the parent company of -290 million yuan, -140 million yuan, -43.596 million yuan, and 49.4496 million yuan for the years 2022 to the first half of 2025, with an expected profit of 78 million to 88 million yuan for 2025, representing a growth of 278.91% to 301.85% compared to the previous year [2] - The total planned investment of 952 million yuan from the fundraising will be allocated to the construction of an interventional medical device industrialization base, research and development projects, and to supplement working capital [2]

Core Viewpoint - The A-share market is experiencing extreme enthusiasm, prompting regulatory measures to cool down the market, indicating a shift towards a "slow bull" market rather than a "crazy bull" market, emphasizing the need for investors to focus on fundamentals rather than emotions [5][6]. Market Sentiment and Regulatory Response - On January 14, the exchange announced an increase in the minimum margin ratio for financing from 80% to 100%, leading to an immediate market downturn [5]. - The regulatory stance is clear: the market can rise, but it should not be driven solely by emotions, and investors must return to fundamentals [6]. Investment Opportunities and Risks - The focus should be on identifying key sectors that are likely to perform well while avoiding those that may pose risks [7][8]. - The analysis will cover 13 high-interest sectors to provide insights on potential investment opportunities [9]. AI Computing Power - The rise of AI infrastructure is supported by increased investments from cloud vendors, with companies like "易中天" (New Yizhong, Zhongji Xuchuang, Tianfu Communication) showing significant stock price increases [11]. - However, the current high valuations may be unsustainable, and without new positive developments, there is a risk of a bubble burst in this sector [11]. Space Computing Industry - The space computing industry is expected to emerge as a significant market, with technologies deploying data centers in space to address ground-based limitations [13][15]. - China's advancements in space computing are supported by government initiatives, with plans for a comprehensive deployment strategy by 2025 [17][18]. Humanoid Robots - The humanoid robot sector is anticipated to see differentiation by 2026, with industrial applications being the primary focus, while household robots remain underdeveloped [20][22]. - Companies like 优必选 (UBTECH) are ramping up production, with expectations of significant output increases in the coming years [22][23]. Semiconductor Equipment - Domestic wafer fabs are planning expansions to meet AI chip demand and enhance production capacity, which will benefit semiconductor equipment suppliers [25][26]. Controlled Nuclear Fusion - The commercialization of controlled nuclear fusion is accelerating, with multiple technological pathways being explored [28][30]. - China is making significant strides in fusion energy, with projects like EAST and BEST expected to lead to practical applications by 2027 [32][33]. Commercial Aerospace - The commercial aerospace sector is experiencing a surge, driven by fears of missing out on investment opportunities, although there are concerns about the sustainability of this growth [41][42]. - China's satellite deployment is rapidly increasing, positioning the country as a major player in the global space race [44]. Photovoltaics - The photovoltaic sector is expected to reach a turning point in 2026, driven by supply-side adjustments and improved fundamentals [47][51]. - The cancellation of export tax rebates is likely to increase costs for exporters, benefiting larger firms with economies of scale [51][52]. Consumer Sector - The consumer sector is seen as a safe haven during market volatility, with specific focus areas including media, service consumption, and premium goods like liquor [66][70]. - The overall consumer demand is expected to recover gradually, but structural changes may lead to a lack of strong support for broad-based growth [67]. Banking Sector - The banking sector has shown resilience despite fundamental pressures, with attractive dividend yields drawing in long-term investors [72][73]. - However, the sector is unlikely to lead the market due to its lower growth potential compared to technology and growth stocks [74]. Insurance Sector - The insurance sector has outperformed banks, benefiting from stock market recovery and expected growth in both asset and liability sides [76]. - The aging population is likely to increase the importance of insurance companies in key areas like healthcare and retirement [76]. Brokerage Firms - Brokerage firms have seen strong earnings growth but face challenges in maintaining investor interest due to perceived volatility and lack of long-term growth [77].

Group 1 - The construction of a "super factory" by Brain Tiger Technology in Jiangxi marks a significant transition from laboratory research to large-scale production in the brain-computer interface (BCI) sector, aiming for stable supply of tens of thousands of units [1][6] - The factory will produce China's first and the world's second fully implanted, fully wireless, and fully functional BCI system, highlighting the growing market potential across healthcare, consumer electronics, and military applications [1][6] - Global developments include Neuralink's announcement to start large-scale production of BCI devices by 2026, indicating a shift from clinical validation to industrialization [1][6] Group 2 - The Chinese government is actively promoting the BCI industry, with a policy document aiming for breakthroughs in key technologies by 2027 and a robust industry system by 2030 [2][7] - The "14th Five-Year Plan" identifies BCI as a future industry requiring strategic development, with various regions setting clear goals for BCI technology and product applications [2][7] - Successful surgeries have been performed on high-level paraplegics using BCI technology, enabling patients to control devices and participate in rehabilitation and employment activities [2][7] Group 3 - The BCI sector has attracted significant investment, with the A-share market showing a cumulative increase of over 20% since 2026, and several stocks rising more than 50% [3][8] - As of January 13, 2023, the financing balance for 26 BCI-related stocks reached nearly 25.5 billion yuan, a 15% increase from the previous year, with many stocks seeing substantial increases in their financing [3][8] - Notable companies include Meihua Medical, with a financing balance of 470 million yuan and a 255% increase, and Innovation Medical, with a balance of 744 million yuan and a 105% increase [3][8][9]